Abciximab
BLOOD AND BLOOD FORMING ORGANS
Also known as: 7E3, reopro
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Abciximab is a drug catalogued in DrugCentral. It was first approved by the FDA in 1993. DrugCentral lists 1 molecular target, including ITGB3|ITGA2B. Recorded indications include Percutaneous coronary intervention.
- Molecular targets: ITGB3|ITGA2B (1 listed in DrugCentral).
- Indications: Percutaneous coronary intervention.
- ATC code: B01AC13 (Platelet aggregation inhibitors excl. heparin).
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Percutaneous coronary intervention
Mechanism & targets
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Integrin alpha-IIb/beta-3 | ITGB3|ITGA2B | other | — |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1993-12-16 | FDA | — | CENTOCOR INC |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
B01AC13 | BLOOD AND BLOOD FORMING ORGANS › ANTITHROMBOTIC AGENTS › ANTITHROMBOTIC AGENTS › Platelet aggregation inhibitors excl. heparin |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Thrombocytopenia | 165.1 |
| Vascular stent thrombosis | 128.2 |
Chemical structure
| Molecular formula | — |
|---|---|
| Molecular weight | — |
| CAS number | 143653-53-6 |
| InChIKey | — |
| PubChem CID | — |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Abciximab used for?
DrugCentral lists the following indications for Abciximab: Percutaneous coronary intervention.
How does Abciximab work?
Its molecular targets in DrugCentral include ITGB3|ITGA2B.
When was Abciximab first approved?
Abciximab was first approved by the FDA in 1993.
Browse: all drugs starting with A · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 4950 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1201584 — compound record and bioactivity
- DrugBank DB00054 — drug record
- FDA UNII X85G7936GV — substance identity
- DailyMed: FDA labels for Abciximab — current prescribing information (label search)
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.